guest ::
| Home > Publications Database > Dynamics of synaptic damage in severe traumatic brain injury revealed by cerebrospinal fluid SNAP-25 and VILIP-1. > print |
| Home > Publications Database > Dynamics of synaptic damage in severe traumatic brain injury revealed by cerebrospinal fluid SNAP-25 and VILIP-1. > print |
| 001 | 272981 | ||
| 005 | 20250127091741.0 | ||
| 024 | 7 | _ | |a pmc:PMC11671962 |2 pmc |
| 024 | 7 | _ | |a 10.1136/jnnp-2024-333413 |2 doi |
| 024 | 7 | _ | |a pmid:38825349 |2 pmid |
| 024 | 7 | _ | |a 0022-3050 |2 ISSN |
| 024 | 7 | _ | |a 0266-8637 |2 ISSN |
| 024 | 7 | _ | |a 0368-329X |2 ISSN |
| 024 | 7 | _ | |a 1468-330X |2 ISSN |
| 024 | 7 | _ | |a 2753-0477 |2 ISSN |
| 024 | 7 | _ | |a 2753-0485 |2 ISSN |
| 024 | 7 | _ | |a altmetric:164109937 |2 altmetric |
| 037 | _ | _ | |a DZNE-2024-01360 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Olde Heuvel, Florian |b 0 |
| 245 | _ | _ | |a Dynamics of synaptic damage in severe traumatic brain injury revealed by cerebrospinal fluid SNAP-25 and VILIP-1. |
| 260 | _ | _ | |a London |c 2024 |b BMJ Publishing Group |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1733309261_24135 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Biomarkers of neuronal, glial cells and inflammation in traumatic brain injury (TBI) are available but they do not specifically reflect the damage to synapses, which represent the bulk volume of the brain. Experimental models have demonstrated extensive involvement of synapses in acute TBI, but biomarkers of synaptic damage in human patients have not been explored.Single-molecule array assays were used to measure synaptosomal-associated protein-25 (SNAP-25) and visinin-like protein 1 (VILIP-1) (along with neurofilament light chain (NFL), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillar acidic protein (GFAP), interleukin-6 (IL-6) and interleukin-8 (IL-8)) in ventricular cerebrospinal fluid (CSF) samples longitudinally acquired during the intensive care unit (ICU) stay of 42 patients with severe TBI or 22 uninjured controls.CSF levels of SNAP-25 and VILIP-1 are strongly elevated early after severe TBI and decline in the first few days. SNAP-25 and VILIP-1 correlate with inflammatory markers at two distinct timepoints (around D1 and then again at D5) in follow-up. SNAP-25 and VILIP-1 on the day-of-injury have better sensitivity and specificity for unfavourable outcome at 6 months than NFL, UCH-L1 or GFAP. Later elevation of SNAP-25 was associated with poorer outcome.Synaptic damage markers are acutely elevated in severe TBI and predict long-term outcomes, as well as, or better than, markers of neuroaxonal injury. Synaptic damage correlates with initial injury and with a later phase of secondary inflammatory injury. |
| 536 | _ | _ | |a 352 - Disease Mechanisms (POF4-352) |0 G:(DE-HGF)POF4-352 |c POF4-352 |f POF IV |x 0 |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a traumatic brain injury |2 Other |
| 650 | _ | 7 | |a Synaptosomal-Associated Protein 25 |2 NLM Chemicals |
| 650 | _ | 7 | |a Biomarkers |2 NLM Chemicals |
| 650 | _ | 7 | |a Neurocalcin |2 NLM Chemicals |
| 650 | _ | 7 | |a neurofilament protein L |2 NLM Chemicals |
| 650 | _ | 7 | |a VSNL1 protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a Neurofilament Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a SNAP25 protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a Ubiquitin Thiolesterase |0 EC 3.4.19.12 |2 NLM Chemicals |
| 650 | _ | 7 | |a Glial Fibrillary Acidic Protein |2 NLM Chemicals |
| 650 | _ | 7 | |a Interleukin-6 |2 NLM Chemicals |
| 650 | _ | 7 | |a UCHL1 protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a GFAP protein, human |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Brain Injuries, Traumatic: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Synaptosomal-Associated Protein 25: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Adult |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Biomarkers: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Neurocalcin: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Synapses: pathology |2 MeSH |
| 650 | _ | 2 | |a Neurofilament Proteins: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Ubiquitin Thiolesterase: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Glial Fibrillary Acidic Protein: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Interleukin-6: cerebrospinal fluid |2 MeSH |
| 650 | _ | 2 | |a Young Adult |2 MeSH |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 700 | 1 | _ | |a Li, Zhenghui |b 1 |
| 700 | 1 | _ | |a Riedel, Daniel |0 P:(DE-2719)9002961 |b 2 |u dzne |
| 700 | 1 | _ | |a Halbgebauer, Steffen |0 P:(DE-2719)9002026 |b 3 |u dzne |
| 700 | 1 | _ | |a Oeckl, Patrick |0 P:(DE-2719)9001560 |b 4 |u dzne |
| 700 | 1 | _ | |a Mayer, Benjamin |b 5 |
| 700 | 1 | _ | |a Gotzman, Nina |b 6 |
| 700 | 1 | _ | |a Shultz, Sandy |0 0000-0002-2525-8775 |b 7 |
| 700 | 1 | _ | |a Semple, Bridgette |b 8 |
| 700 | 1 | _ | |a Tumani, Hayrettin |0 P:(DE-2719)9002007 |b 9 |u dzne |
| 700 | 1 | _ | |a Ludolph, Albert C |0 P:(DE-2719)2812633 |b 10 |u dzne |
| 700 | 1 | _ | |a Böckers, Tobias |0 P:(DE-2719)2812855 |b 11 |u dzne |
| 700 | 1 | _ | |a Morganti-Kossmann, Cristina |b 12 |
| 700 | 1 | _ | |a Otto, Markus |0 0000-0003-4273-4267 |b 13 |
| 700 | 1 | _ | |a Roselli, Francesco |0 P:(DE-2719)2812851 |b 14 |e Last author |u dzne |
| 773 | _ | _ | |a 10.1136/jnnp-2024-333413 |g Vol. 95, no. 12, p. 1158 - 1167 |0 PERI:(DE-600)1480429-3 |n 12 |p 1158 - 1167 |t Journal of neurology, neurosurgery, and psychiatry |v 95 |y 2024 |x 0022-3050 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/272981/files/DZNE-2024-01360%20SUP.pdf |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/272981/files/DZNE-2024-01360.pdf |
| 856 | 4 | _ | |x pdfa |u https://pub.dzne.de/record/272981/files/DZNE-2024-01360%20SUP.pdf?subformat=pdfa |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/272981/files/DZNE-2024-01360.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:272981 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 2 |6 P:(DE-2719)9002961 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 3 |6 P:(DE-2719)9002026 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 4 |6 P:(DE-2719)9001560 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 9 |6 P:(DE-2719)9002007 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 10 |6 P:(DE-2719)2812633 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 11 |6 P:(DE-2719)2812855 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 14 |6 P:(DE-2719)2812851 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-352 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Mechanisms |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 1 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-08-24 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NEUROL NEUROSUR PS : 2022 |d 2023-08-24 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b J NEUROL NEUROSUR PS : 2022 |d 2023-08-24 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-24 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0 |0 LIC:(DE-HGF)CCBYNC4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-08-24 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-08-24 |
| 915 | _ | _ | |a National-Konsortium |0 StatID:(DE-HGF)0430 |2 StatID |d 2023-08-24 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-24 |
| 920 | 1 | _ | |0 I:(DE-2719)1910001 |k AG Roselli |l Metabolic Changes in Neurodegeneration |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)5000077 |k Clinical Study Center (Ulm) |l Clinical Study Center (Ulm) |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1910001 |
| 980 | _ | _ | |a I:(DE-2719)5000077 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|